Medical Device | March 22, 2022
Thermo Fisher Scientific to showcase global innovation at DCAT Week 2022
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
On track to complete the BLA submission in the first half of 2022
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
